bioRxivPharmacology & Toxicology
Istaroxime metabolite PST3093 selectively stimulates SERCA2a and reverses disease-induced changes in cardiac function
M. Arici, M. Ferrandi, P. Barassi, S.-C. Hsu, E. Torre, A. Luraghi, C. Ronchi, G.-J. Chang, F. Peri, P. Ferrari, G. Bianchi, M. Rocchetti, A. Zaza
Abstract
BackgroundHeart failure (HF) therapeutic toolkit would strongly benefit from the availability of ino-lusitropic agents with a favorable pharmacodynamics and safety profile. Istaroxime is a promising agent, which combines Na+/K+ pump inhibition with SERCA2a stimulation; however, it has a very short half-life and extensive metabolism to a molecule, named PST3093. The present work aims to investigate whether PST3093, still retains the pharmacodynamic and pharmacokinetic properties of its parent compound. MethodsWe studied PST3093 for its effects on SERCA2a and Na+/K+ ATPase activities, Ca2+ dynamics in isolated myocytes and hemodynamic effects in an in-vivo rat model of diabetic (streptozotocin (STZ)-induced) cardiomyopathy. ResultsIstaroxime infusion in HF patients led to accumulation of PST3093 in the plasma; clearance was substantially slower for PST3093 than for istaroxime. In cardiac rat preparations PST3093 did not inhibit the Na+/K+ ATPase activity, but retained SERCA2a stimulatory activity. In in-vivo echocardiographic assessment, PST3093 improved overall cardiac performance and reversed most STZ-induced abnormalities. PST3093 i.v. toxicity was considerably lower than that of istaroxime and it failed to significantly interact with 50 off-targets. ConclusionsOverall, PST3093 is a "selective" SERCA2a activator, the prototype of a novel pharmacodynamic category with a potential in the ino-lusitropic approach to HF with prevailing diastolic dysfunction. Its pharmacodynamics are peculiar and its pharmacokinetics are suitable to prolong the cardiac beneficial effect of istaroxime infusion. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=137 SRC="FIGDIR/small/455204v3_ufig1.gif" ALT="Figure 1"> View larger version (34K): org.highwire.dtl.DTLVardef@bc9220org.highwire.dtl.DTLVardef@1d7a6eorg.highwire.dtl.DTLVardef@1510c71org.highwire.dtl.DTLVardef@7f037_HPS_FORMAT_FIGEXP M_FIG C_FIG
- organism: rat
- assay: bulk RNA-seq
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Species-Dependent Limitations of Murine Myocardium for Investigating the Combined Inotropic Effects of SERCA2a Stimulation and Myofilament Ca2+ Sensitization
Francesca Misitano, Natasha Giacomelli, … Francesco Lodola·bioRxiv·Nov 2, 2026
- Inhibition of Cardiac p38 Highlights the Role of the Phosphoproteome in Heart Failure Progression
Sogol Sedighi, Ting Liu, … D. Brian Foster·ACS OmegaPeer-reviewed·Aug 6, 2025
- Slow Calcium Removal Prolongs Ventricular Relaxation in Mice with HFpEF
Tamzin Zawadzki, Diana S. Usai, … Morten Bækgaard Thomsen·bioRxiv·Sep 10, 2025
- Increased spontaneous Ca2+ activity in Cardiac Purkinje cells after myocardial infarction; A consequence of a dramatic shift of SERCA isoforms as potential adaptation to acute ischemia?
B. D. Stuyvers, P. A. Boyden, … T. Benoukraf·bioRxiv·Oct 23, 2023
- The Ca2+-Sensitivity of Contraction is Increased in the Left Atrium and Left Ventricle of Patients with Ischemic Heart Failure
Gregory N. Milburn, Chloe I Roth, … Kenneth S. Campbell·bioRxiv·Jul 1, 2026
- Modulating Cardiac Energetics in Cardio-Metabolic Syndromes: A mechanistic, hyperpolarized MR Trial of Ninerafaxstat Treatment
Moritz Hundertmark, Adrienne. G. Siu, … Oliver J. Rider·bioRxiv·Apr 24, 2024